Mike Taylor is a prominent scientist, virologist, healthcare investor, and Portfolio Manager of PINK Simplify Health Care ETF, the first ETF committed to donating all net profits to the Susan G. Komen breast cancer organization. Taylor is a 20-year hedge fund veteran who specializes in healthcare investing. Prior to PINK, he was Portfolio Manager and Managing Director of Critical Mass Partners, and has managed hedged and factor-neutral portfolios with a gross amount of over $1 billion at funds including Millennium Management, Citadel and Diamondback Capital. Taylor is regarded to have built and run one of the best-performing Healthcare funds on Wall Street.
Taylor manages the fund in providing investors with competitive exposure to healthcare and biotechnology markets.
PINK is the first 100% pro bono ETF focused on the health care sector and net profits will be donated for the benefit of the Susan G. Komen foundation on an annual basis.
The fund focuses on the healthcare and biotechnology sectors, combining the active stock selection, rigorous company and industry research, and due diligence processes.
EXPERTISE & EARLY CAREER
Taylor is a renowned hedge fund and healthcare investor, and has managed portfolios for major hedge funds.
He began his career as a Scientist at GenVac, where he developed predominantly viral vector-based Gene Therapeutic Drugs for the BioPharma industry.
He entered the investment industry in 2001 as the Head of Healthcare at OppenheimerFunds, where he oversaw the day-to-day operations, portfolio selection/trades, and research staff.
He managed hedged and factor-neutral portfolios with a gross amount of over $1 billion at funds including Millennium Management, Citadel, and Diamondback Capital.
Prior to PINK, he served as the Portfolio Manager and Managing Director of CriticalMass Partners, where he specialized in Healthcare Investing.
MEDIA & APPEARANCES
He has appeared in Morningstar, MarketWatch, Hedgeye Risk Management, and Real Vision.